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INTRODUCTION
Polymers are the primary materials for drug delivery devices and scaffold fabrication in tissue engineering applications. and many types of biodegradable polymeric materials have been already used in this field. A wide variety of natural and synthetic biodegradable polymers have been investigated in this field. Naturally derived polymers have the potential advantage of biological recognition that may positively support cell adhesion and function, but the use of these natural polymers is limited due to their higher costs and questionable purity and poor mechanical properties. Synthetic biodegradable polymers have been increasingly used to deliver drugs, since they are free from most of the problems associated with the natural polymers. They have relatively good mechanical strength and their shape and degradation rate can be easily modified, but their surfaces are hydrophobic and lack of cell-recognition signals. Poly(amides), poly (amino acids), poly (alkyl-a-cyano acrylates), poly(esters), poly (orthoesters), poly (urethanes), and poly(acrylamides) have been used to prepare various drug loaded devices. Among them, the thermoplastic aliphatic poly(esters) like PLA, PGA, and especially PLGA have generated tremendous interest due to their excellent biocompatibility and biodegradability (3, 38, 61) . Poly(D,L-lactide-co-glycolide) (PLGA) and its various derivatives have been the center focus for developing nano/microparticles encapsulating therapeutic drugs in controlled release (CR) applications due to their advantages over the conventional devices that include extended release rates up to days, weeks or months, in addition to their biocompatibility/ biodegradability and ease of administration via injection (11, 38, 44, 54) . Macromolecular drugs such as proteins, peptides, genes, vaccines, antigens, human growth factors, vascular endothelial growth factors etc., are successfully incorporated into PLGA or PLGA based nano/microparticles. Also, PLGA has been approved by the Food and Drug Administration (FDA) for drug delivery device (1, 6, 17, 38, 42, 63, 71, 72) . The list of FDA approved CR products of PLGA is given in Table 1 (54) . In this review, physicochemical and biodegradable properties of PLGA and PLGA based drug delivery devices for tissue engineering and regenerative medicine will be presented.
PHYSICOCHEMICAL PROPERTIES OF
PLGA Poly(lactic acid) (PLA) is a linear aliphatic thermoplastic polyester, produced by polymerization of lactide, a cyclic dimer derived from lactic acid. It is a chiral molecule and can be produced as poly (L-lactide), poly (D-lactide), and the racemic poly (D,L-lactide). PLA is soluble in common organic solvents. Poly(glycolic acid) (PGA) is the simplest linear, aliphatic polyester. Since PGA is highly crystalline, it has a high melting point and low solubility in organic solvents. PGA's high crystallinity is because of its chemical structure lacking the methyl side groups of the PLA (56, 61, 66) . PLGA is a copolymer of lactide and glycolide, which is synthesized by means of random ring-opening and when PGA randomly copolymerized (30-50 %) with PLA, resulting copolymer (PLGA) retains physical properties more readily amenable to processing Table 1 . PLGA-based microparticles available in the market (54) . (those of low-melting thermoplastic with good solubility in common solvents). The degradation rate of PLGA is much faster than that of PLA due to the component glycolic acid in the backbone, and in addition the degradation rate can be adjusted by varying the amounts of glycolic acid and lactic acid (7, 18, 38, 39, 66, 81, 87) . The Tg (glass transition temperature) of the PLGA copolymers are above the physiological temperature of 37ºC and hence they are glassy in nature. They have a fairly rigid chain structure which gives them significant mechanical strength to be formulated as drug delivery devices (3, 50, 81) . Tg of PLGAs decrease with decrease of their lactide content in the copolymer composition and with decrease in their molecular weight (3, 40) . PLGA polymers are subjected to physical stress when using as drug delivery devices so they should have a considerable mechanical strength (50, 81) . Different factors like the molecular weight, copolymer composition (lactide/glycolide ratio), crystallinity and geometric regularity of individual chains significantly affect the mechanical strength of the polymer (39, 50, 81) .
BIOLOGICAL PROPERTIES AND BIODEGRADATION OF PLGA
The design and development of biodegradable drug delivery devices for therapeutical application require a well understanding of the in vivo biodegradation phenomena and also the cellular and tissue responses which determine the biocompatibility of the biodegradable drug delivery devices (69) . PLGA is one of the most successfully used biodegradable polymer because it undergoes hydrolysis in the body to produce the biodegradable and biocompatible metabolite monomers (lactic acid and glycolic acid) that are eventually removed from the body by the citric acid cycle (Fig. 1) . Polymer biodegradation products are formed at a very slow rate and hence they do not affect the normal cell function. Since the body effectively deals with these two monomers, there is very minimal or no systemic toxicity associated by using PLGA for drug delivery or biomaterial applications (7, 34, 46, 58) . The drug entrapped in the PLGA matrix system is released at a sustained rate through diffusion of the drug and by degradation of the polymer matrix ( Fig. 2 ) (7, 58, 69) . Figure 1 . PLGA undergoes hydrolysis in the body to produce lactic acid and glycolic acid (7) . Figure 2 . The drug entrapped in the PLGA matrix system is released by degradation of the polymer matrix (7) .
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The role of enzymes in biodegradation of PLGA is contraversial -with early literature concluding that spontaneous hydrolysis was the only mechanism. Further work indicates the conclusion that the PLGA biodegradation does not involve any enzymatic activity and is purely through hydrolysis. However, enzymes could potentially play a role in degradation for polymers in the rubbery state and enzymatic role in PLGA breakdown based upon the difference in the in vitro and in vivo degradation rates (50, 66, 81) . The PLGA polymer biodegrades into lactic and glycolic acids (4, 18, 39, 50, 74, 81) . Lactic acid, a normal byproduct of anaerobic metabolism in the human body, which is incorporated into the tricarboxylic acid (TCA) cycle and is metabolized and subsequently eliminated from the body as carbon dioxide and water (4) . Glycolic acid is either excreted unchanged in the kidney or it enters the tricarboxylic acid cycle and eventually eliminated as carbon dioxide and water. The degradation time of PLGA can be controlled from weeks to over a year by varying both the ratio of monomers and the processing condition (4, 61) .
FACTORS AFFECTING THE BIODEGRADATION OF PLGA
Chemical composition, additives, crystallinity, porosity, molecular weight and molecular weight distribution, water permeability and solubility, mechanism of hydrolysis, morphology, device dimensions, glass transition temperature, sterilization, site of implantation are the factors affecting the biodegradation behaviour of PLGA based drug delivery devices (69) . Shive and Anderson (69) injected rats intramuscularly in the leg with norethistrone or lypressin microspheres prepared with radiolabelled PLGA microspheres of varying lactide:gycolide mole ratio in order to determine the biodegradation kinetics of microspheres prepared with lactide/gycolide exipients. The radiolabel was incorporated into the excipient by using 14 C-DL-lactide monomer during its polymerization. Altering the chemical composition by increasing the gycolide mole ratio in the copolymer increases the rate of biodegradation ( Fig. 3 ) (69) . Additives through their acidic or basic nature as well as loading level in the case of therapeutic agents may markedly affect the degradation rate of microspheres. Basic compounds can catalyze ester linkage scission and thus accelerate polymer degradation. On the other hand, appropriate amounts of basic compounds can neutralize carboxyl end groups and thus decrease the rate of degradation. This potential effect by the acidic/basic nature of the therapeutic agent incorporated must be considered in the design of PLGA based drug delivery devices (51) . The crystallinity of the homopolymer or copolymer comprising the microcapsule may play a significant role in modulating the degradation rate. For semicrystalline polyesters, degradation first occurs in the amorphous domains and later in the crystalline regions. During the degradation process, the crystallinity gradually increases resulting in a high crystalline material which is much more resistant to hydrolysis than the starting polymer (8) . Porosity of the microspheres may play a major role in enhancing the rate of biodegradation, especially when the pore dimensions are sufficiently large enough to permit cellular migration into the pores of the microsphere (69) . Molecular weight and molecular weight distribution may play a role in the degradation behaviour. A large molecular weight distribution would indicate relatively large numbers of carboxylic end groups which can facilitate the autocatalytic degradation of the polymer chains. (68) .
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Large or wide molecular weight distributions thus would be expected to accelerate the rate of degradation whereas a narrow molecular weight distribution would have fewer carboxylic end groups available for catalysis (69) . Kamei and coworkers carried out a study in which two molecular weights of the copolymer were used: 10000 and 20000. It was demonstrated that the 10 000 molecular weight polymer degraded approximately twice as fast as the 20 000 molecular weight polymer (41) .
PLGA BASED DRUG DELIVERY DEVICES
PLGA has been used in various areas, such as the controlled release of encapsulated drugs, tissue engineering (79) , healing of bone defects (9) and in vaccines (26) . The reasons for the widespread use of PLGA are its biodegradability, its biocompatibility, and the fact that drug products containing PLGA have been approved for parenteral use by regulatory authorities around the world (28) . The disadvantage associated with PLGA is the production of acids upon degradation. Several techniques for the stabilization of acid-sensitive drugs have been investigated (12, 36, 88) . Advantages of PLGAs are that they are commercially available with very different physico-chemical properties, and that the drug release profile can be tailored by selecting PLGAs with the appropriate properties, such as molecular weight (Mw) and the lactide: gycolide ratio (89) . The duration of drug release can be varied from hours (62) to several months (48) . Furthermore, pulsed drug release is also possible (24) . Blending or co-polymerizing PLGA with other materials, or encapsulating PLGA microparticles in gels, further extends the possibility of controlling drug release (54) . Numerous active pharmaceutical ingredients have been encapsulated in PLGA-based drug delivery systems (DDSs) with proven therapeutic effect in vivo, or have been released in concentrations considered sufficient for therapeutic effect, for example, siRNA (55) , proteins (32) , anti-cancer drugs (53) , analgesic (84) , antibiotics (59) , and vaccines (19) . Among the different forms of PLGA-based DDSs, microspheres or microparticles are the most common. Other types include nanoparticles (68) , films (45) , cylinders (22) , in situ forming implants or microparticles (23) , scaffolds (82) , and foams (57) . PLGA implants may be surgically inserted at the desired location, giving the advantage of local drug delivery of, for example, antibiotics or anti-cancer drugs (80, 83) . The manufacturing techniques of PLGA particles are solvent evaporation and solvent extraction process, phase separation (coaservation) process and spray drying (38) .
PLGA based drug delivery devices for tissue engineering
Tissue engineering and regenerative medicine are emerging disciplines of biomedical research that promote the regeneration of tissues or the replacement of failing or multifunctioning organs. Three fundamental "tools", namely cells, scaffolds and bioactive molecules are used at the repairing and restoring the damaged tissue function (20, 52) . The combination of adequate cells, scaffolds (that support and direct the growth of cells, and present appropriate physicochemical properties, mechanical strength and biodegradation profile) and bioactive molecules are used. These bioactive molecules essentially include proteins stimulating cell migration, proliferation or inducing cell differentiation, such as growth and neurotrophic factors (47) . The selection of biomaterials plays a key role in the design and development of tissue engineering product development. Although the classical selection criterian for a safe, stable implant dictated choosing a passive, "inert" material, it is now understood that any such device will elicit a celluler response (60) . The incorporation of these bioactive proteins in PLGA nanoparticles could present several advantages. These systems in general can be used to provide targeted (cellular or tissue) delivery of drugs, which localized effect represents also an important benefit, because the administration of these proteins could present undesired side effects when they activate nontarget areas, improve bioavailability, sustain release of drugs or solubilize drugs for systemic delivery. This process can be adapted to protect therapeutic agents against enzymatic degradation (20, 31) . Poly(lactic-co-glycolic acid) based drug delivery devices for tissue engineering and regenerative medicine 91
PLGA based drug delivery devices for vascular engineering
In tissue engineering, vascularization is one of the first requirements to achieve tissue regeneration. Complex organ constructs need a vascular supply system to guarantee survival and to render biological functions. Substantial efforts have been made over the past 10 years to create these vascular systems. There are three main approaches for engineering vascularized systems: (1) stimulating rapid vessel growth in a vascular implants with angiogenic factors, (2) seeding biodegradable bulk polymer scaffolds with endothelial cells and angiogenic factors, and (3) prevascularizing the acellular structures with stem cells before implantation (29, 30, 73, 78) . The delivery of angiogenic factors from implants has been widely investigated for establishing a vascular network within the developing tissue (21) . Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogenic peptide and plays a key role in vasculogenesis and angiogenesis (25) . Incorporation of VEGF into PLGA scaffolds or into microspheres has shown the potential to protect and locally deliver VEGF at a more constant rate, leading to site-specific angiogenesis (21) . Formiga et al. also prepared VEGF loaded microparticles and it was demonstrated that a single cytokine, VEGF, could exert not only an angiogenic but also an arteriogenic effect when delivered in vivo in a sustained manner, which translates into positive remodeling of the heart. Moreover, the use of microparticles allowed a dose-controlled release of the protein that can be easily and safely translated to patients (27) .
PLGA based drug delivery devices for nerve regeneration
Biodegradable synthetic nerve conduits have emerged as an alternative to autogenous grafts, and growth factors have been applied into the conduit lumen to increase nerve regeneration (70) . Schwann cells and the basal lamina, other than growth factors, also play a critical role in the early phase of nerve regeneration (14) . An ideal alternative conduit material including neurological substrates as well as growth factors could replace the autogenous nerve graft. The physiochemical and biological properties of PLGA can be tailored to match different application requirements, and some chemical modifications enable the materials effectively to entrap support cells (Schwann cells, laminins etc.) or bioactive molecules (nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3)) for controlled delivery during nerve regeneration (33) . Bini et al. (13) used PLGA in the ratio of 10:90 for the microbraiding of conduits which presented the advantages of flexibility, ease of suturing to the proximal and distal stumps, as well as a high degree of permeability for the exchange of nutrients. When implanted to bridge 1,2 cm gaps of the adult rat sciatic nerve, the conduit became filled with a fibrin matrix and by 1 month post operation, 9 of 10 rats revealed successful nerve regeneration. Furthermore, a thin fibrous tissue capsule which formed around the implant became vascularized suggesting good graft-host integration (13) . VEGF-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres were prepared (1, 42, 71, 72) . Controlled release of VEGF was achieved during a 30-day period (Fig. 4 ) (43, 72) and with the help of an experimental model in rats, a nerve graft was prefabricated serving as a conduit instead of autologous nerve. The prefabricated nerve graft with the axons in an autogenous sheath was histologically similar to a real nerve. Nerve regeneration with the prefabricated nerve graft using VEGF loaded PLGA microspheres were similar to that achieved with an autogenous nerve graft for repairing nerve defects (42, 43) .
PLGA based drug delivery devices for cartilage tissue engineering
The demand for tissue engineered cartilage is immense because of the tissue's poor intrinsic healing potential; untreated degenerative and traumatic cartilage lesions often progress to degenerative arthritis (67, 75) . Thus, applications in tissue engineering that improve cartilage repair have a high clinical impact. Biodegradable delivery devices that release bioactive insulin in a sustained manner are essential for the engineering of cartilage because insulin has a low half-life in vivo and is unstable in the presence of cartilage (15, 16) . Insulin-loaded PLGA microspheres were prepared by Andreas et al. (2) and employed in a high density threedimensional (3D) in vitro cartilage engineering model. PLGA microspheres prepared by the w/o/w procedure showed sustained release of structurally intact and biologically active insulin that promoted the formation of cartilage-specific extracellular matrix (ECM) and thus represented a potent delivery device for application (2) . Apart from microspheres, PLGA scaffolds were also used for cartilage tissue engineering. Zhang et al. (86) seeded porcine articular chondrocytes on the longitudinal oriented PLGA scaffolds (mimicking the microstructure of deep zone of articular cartilage) and cultured the samples in vitro for 12 weeks followed by another 12 weeks of subcutaneous implantation in nude mice. Cell migration on scaffolds, extracellular matrix production, as well as size, structure, and mechanical property of engineered cartilage were analyzed to evaluate the effects of the scaffold orientation on the structure and function of 3D cartilage formation. Oriented structure of scaffolds enhanced thickness, homogeneity, and mechanical property of in vitro engineered cartilage and thus provided a clue for improving in vitro cartilage regeneration. Most importantly, the in vitro engineered cartilage based on oriented scaffolds showed homogeneous and mature cartilage structure with abundant cartilage-specific ECM deposition after in vivo implantation, indicating a potential for in vivo cartilage repair (86) .
PLGA based drug delivery devices for bone tissue engineering
Bone tissue engineering is a highly interdisciplinary field that seeks to tackle the most challenging bone related clinical issues. The major components of bone tissue engineering that includes as well the use of 3-D systems are porous biodegradable scaffold, bone forming cells, and growth factors (35) . Bone morphogenetic protein (BMP) is an effective growth factor that increases bone formation and recovery from diseases (76) . During the process of bone formation, signals from BMPs trigger the differentiation of stem cells, which are recruited to the site of injury, into bone forming cells (64) . Among them, BMP-2 and BMP-7, have been described as the most effective to induce complete bone morphogenesis and have been currently approved by FDA (10, 77) . In order to provide this sequential time pattern of administration and also to increase the stability of the growth factors, BMP-2 was encapsulated in PLGA nanoparticles for an early release by Yilgor et al. (85) When tested in an in vitro bioassay of the osteogenic differentiation into osteoblasts of rat bone marrow mesenchymal stem cells, a synergistic effect was observed with the sequential delivery of the BMPs in contrast with their single and simultaneous (using PLGA nanoparticles for both BMPs) delivery.
In another study, the release kinetics of recombinant human bone morphogenetic protein-2 (rhBMP-2) loaded PLGA/calcium phosphate cement (PLGA/Ca-P cement) composites (43) . 6 vascularized suggesting good graft-host integration .
VEGF-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres were prepared (1, 42, 71, 72) . Controlled release of VEGF was achieved during a 30-day period (Fig. 4 ) (43, 72) and with the help of an experimental model in rats, a nerve graft was prefabricated serving as a conduit instead of autologous nerve. The prefabricated nerve graft with the axons in an autogenous sheath was histologically similar to a real nerve. Nerve regeneration with the prefabricated nerve graft using VEGF loaded PLGA microspheres were similar to that achieved with an autogenous nerve graft for repairing nerve defects (42, 43) . Figure 4 . In vitro release profile of VEGF from PLGA microspheres during a 30 day period (43) .
PLGA based drug delivery devices for cartilage tissue engineering
The demand for tissue engineered cartilage is immense because of the tissue's poor intrinsic healing potential; untreated degenerative and traumatic cartilage lesions often progress to degenerative arthritis (67, 75) . Thus, applications in tissue engineering that improve cartilage repair have a high clinical impact. Biodegradable delivery devices that release bioactive insulin in a sustained manner are essential for the engineering of cartilage because insulin has a low half-life in vivo and is unstable in the presence of cartilage (15, 16) . Insulin-loaded PLGA microspheres were prepared by Andreas et al. (2) and employed in a high density three-dimensional (3D) in vitro cartilage engineering model. PLGA microspheres prepared by the w/o/w procedure showed sustained release of structurally intact and biologically active insulin that promoted the formation of cartilage-specific extracellular matrix (ECM) and thus represented a potent delivery device for application (2) . Apart from microspheres, PLGA scaffolds were also used for cartilage tissue engineering. Zhang et al. (86) seeded porcine articular chondrocytes on the longitudinal oriented PLGA scaffolds (mimicking the microstructure of deep zone of articular cartilage) and cultured the samples in vitro for 12 weeks followed by another 12 weeks of subcutaneous implantation in nude mice. Cell migration on scaffolds, extracellular matrix production, as well as size, structure, and mechanical property of engineered cartilage were analyzed to evaluate the effects of the scaffold orientation on the structure and function of 3D cartilage formation. Oriented structure of scaffolds enhanced thickness, homogeneity, and mechanical property of in vitro engineered cartilage and thus provided a clue for improving in vitro cartilage regeneration. Most importantly, the in vitro engineered cartilage based on oriented scaffolds showed homogeneous and mature cartilage structure with abundant cartilage-specific ECM deposition after in vivo implantation, indicating a potential for in vivo cartilage repair (86) .
PLGA based drug delivery devices for bone tissue engineering
were studied in vivo. RhBMP-2 was radiolabeled with 131I and entrapped within PLGA microparticles or adsorbed onto the microparticle surface. The in vitro and in vivo evaluation suggested that PLGA/Ca-P cement composites can be considered as sustained slow release vehicles and the release and retention of rhBMP-2 can be modified according to the desired profile to a limited extent, the model was suitable as a scaffold for engineering bone tissue (65) . Hydroxyapatite (HA) has been used extensively alone and in combination with polymers to form composite forms of a bone substitue (4) . Attawia et al. (5) formed porous scaffolds containing PLGA and HA and seeded with osteoblasts harvested from rat calvaria. After only 24 hour, osteoblasts were seen to adhere to exterior surface of the scaffold and also to migrate into the pore structure. In a seperate study, the ability of the PLGA-HA scaffold to support osteoblast proliferation and differentiation as well as mineral formation over 21 days was examined (49) . The scaffolds used in these studies combined the degradability of the PLGA with the mechanical support of HA to form a tissue engineering replacement for bone defects.
Ishaug-Riley et al. (37) cultured neonatal rat calvarial osteoblasts in 90 % porous, 75 : 25 poly(DL-lactic-co-glycolic acid) (PLGA) foam scaffolds for up to 56 days to examine the effects of the cell seeding density, scaffold pore size, and foam thickness on the proliferation and function of the cells in this three-dimensional environment. PLGA foams are suitable substrates for osteoblast growth and differentiated function independent of cell source.
CONCLUSION
PLGA has been used by several researchers in tissue engineering, vascular engineering, nerve regeneration, cartilage tissue engineering and bone tissue engineering. Studies reviewed above show that PLGA is a succeesful biodegradable polymer as a controlled release system and a drug delivery device for tissue engineering and regenerative medicine. The selection of biomaterials plays a key role in the design and development of tissue engineering product development. The main reasons of the frequent use and the success of using PLGA polymer are its safety, biodegradability, biocompatibility. The incorporation of bioactive materials in PLGA drug delivery devices could present several advantages. These systems in general can be used to provide targeted (cellular or tissue) delivery of drugs, which localized effect represents also an important benefit. They improve bioavailability, sustain release of drugs or solubilize drugs for systemic delivery. This process can also be adapted to protect therapeutic agents against enzymatic degradation. As a future prospect, PLGA drug delivery systems are becoming more important for the prevention of tissue rejection, mimic in vivo conditions of the organs. Manufacturing processes should also be considered in order to be able to generate tissues on more of a mass scale. Also, automation of some of the cell culture techniques as well as making the generation and transportation of tissues compatible with surgical techniques should expand the opportunities for future tissue engineers.
